{"a":[{"_":"Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail","$":{"href":"/biotech/novo-nordisk-left-praying-artemis-and-hermes-salvage-program-after-key-phase-3-trial-flops","hreflang":"en"}}]}
Phase 3negativeziltivekimabNegative
AI Analysis
Summary
Novo Nordisk's phase 3 trial of ziltivekimab for chronic kidney disease (CKD) missed its primary endpoint. The company has ongoing Artemis and Hermes trials that may provide opportunities to salvage the program.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial missed its primary endpoint
Importance:8/10
Sentiment:
-0.85
Phase 3 failureCKDclinical trialnegative data
Related Companies
Read the original article
Published by FierceBiotech on July 31, 2026 8:59 AM